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Introduction: Since 2015, increased migration from Asia 
and Africa to Europe has raised public health concerns 
about potential importation of extended-spectrum 
β-lactamase-producing Enterobacteriaceae (ESBL-PE), 
specifically those producing carbapenemases (C-PE), 
into European hospitals. Aims: To inform infection 
control practices about ESBL-PE prevalence in asylum 
seekers and to investigate whether C-PE prevalence 
exceeds that in the German population. Methods: 
Cross-sectional study from April 2016–March 2017. 
Routinely collected stool samples from asylum seekers 
were tested for antibiotic resistant Enterobacteriaceae. 
Country/region of origin and demographic characteris-
tics were explored as risk factors for faecal colonisa-
tion. Results: Of 1,544 individuals, 294 tested positive 
for ESBL-PE colonisation (19.0%; 95% confidence inter-
vals (CI): 17.0–21.0). Asylum seekers originating from 
Afghanistan/Pakistan/Iran had a prevalence of 29.3% 
(95% CI: 25.6–33.2), from Syria 20.4% (95% CI: 16.1–
25.2) and from Eritrea/Somalia 11.9% (95% CI: 8.7–
15.7). CTX-M-15 (79%) and CTX-M-27 (10%) were the 
most common ESBL determinants. Highest ESBL-PE 
prevalences were observed in boys under 10 years and 
women aged 20–39 years (interaction: p = 0.03). No 
individuals tested positive for C-PE. Faecal C-PE colo-
nisation prevalence in asylum seekers was not statis-
tically significantly different from prevalence reported 
in German communities.
Conclusion: In absence of other risk factors, being 
a newly arrived asylum seeker from a region with 
increased faecal ESBL-PE colonisation prevalence is 
not an indicator for C-PE colonisation and thus not a 
reason for pre-emptive screening and isolation upon 
hospital admission.
Introduction
Antibiotic resistance of pathogens and resulting limi-
tations of therapeutic options increase morbidity, mor-
tality and costs [1]. Since the beginning of this century, 
the number of infections caused by extended-spectrum 
β-lactamase-producing Enterobacteriaceae (ESBL-PE) 
has grown rapidly. Of these, carbapenemase-producing 
Enterobacteriaceae (C-PE) are of particular interest, as 
carbapenems are considered compounds of last resort 
against life-threatening infections. Major steps in the 
spread of antibiotic resistance in Enterobacteriaceae 
are horizontal exchange of mobile resistance genes 
into different clones and their dissemination over long 
distances, often facilitated by travel or migration of 
the colonised host [2]. International travel to south/
south-east Asia and Africa was found to be a risk fac-
tor for colonisation [3,4] and subsequent infection with 
ESBL-PE [5]. Introduction of these bacteria into unaf-
fected hospitals is much dreaded since nosocomial 
outbreaks of C-PE have been reported world-wide [6].
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In 2015, Europe was challenged by the arrival of a large 
number of asylum seekers, sparked primarily by the 
Syrian civil war, but also by other conflicts and human-
itarian crises in southern Asia, western Asia, and 
Africa. Reports of high ESBL-PE and C-PE colonisation 
prevalences in hospitalised populations and among 
asylum seekers from these countries/regions [7-12], 
together with data on increased ESBL-PE and C-PE colo-
nisation in returning travellers [3,4] led to discussions 
whether such migration may increase the risk of noso-
comial transmission of multidrug-resistant bacteria in 
European countries with low C-PE prevalence [13].
In April 2016, the European Centre for Disease 
Prevention and Control (ECDC) recommended that indi-
viduals with recent exposure in high prevalence coun-
tries may also be considered for pre-emptive screening 
and isolation upon admission in European hospitals, 
even if they had no history of hospitalisation or antibi-
otic therapy before their arrival in Europe [14]. However, 
published studies regarding ESBL-PE/C-PE colonisation 
of migrants seeking asylum in the European Union are 
limited to research in hospitalised patients [9,10,15,16], 
do not stratify by country/region of origin [9,10,15,16], 
and lack statistical power [10,11,15]. Thus, while these 
studies provide rough estimates of the ESBL-PE/C-PE 
colonisation prevalence in populations that have a pri-
ori an increased likelihood of pre-morbidities, they do 
not represent newly arrived asylum seekers in general 
and thus cannot inform whether country/region of 
origin alone is a sufficient predictor for increased risk 
of ESBL-PE/C-PE colonisation. Therefore, research on 
colonisation status in sufficiently large populations 
recruited outside health care institutions is needed 
to determine whether newly arrived asylum seekers 
in general require pre-emptive screening and isolation 
upon hospital admission [14].
This study aimed to determine the colonisation preva-
lence of ESBL-PE/C-PE in asylum seekers newly arrived 
to the federal state of Rhineland-Palatinate, Germany, 
and to compare whether the prevalence of colonisation 
with C-PE exceeds that reported in the German commu-
nity [17].
Methods
We conducted a cross-sectional study from April 2016–
March 2017, on the prevalence of ESBL-PE and C-PE in 
stool samples from asylum seekers arriving in the fed-
eral state Rhineland-Palatinate, Germany.
Study population
According to federal state law, a medical examination 
including the analysis of one stool sample is manda-
tory for each individual within 1 week of seeking asy-
lum [18]. Upon arrival in one of the 29 refugee reception 
centres in Rhineland-Palatinate, each asylum seeker is 
provided with a sample tube, pictogram and pre-paid 
packaging to be sent to the federal state public health 
laboratories for further processing. There, native stool 
samples are routinely tested for Salmonella spp., Shig
ella  spp. and helminth eggs [19]. Stool samples from 
asylum seekers were split into a routine and a study ali-
quot, given there was sufficient material. We recorded 
country of origin (self-reported), year of birth and sex 
from routinely collected data in pseudo-anonymised 
form using an eight digit number code. Samples from 
42 asylum seekers providing incomplete personal 
information (n=22) or insufficient material (n=20) 
were excluded. Using data from the first 6 months, we 
decided to restrict sampling to subjects from the most 
frequently occurring regions of origin: Syria (Western 
Asia), Afghanistan, Pakistan and Iran (all South Asia), 
as well as Eritrea and Somalia (both East Africa).
Sample size
We powered our study to provide evidence against the 
null hypothesis: ‘there is no difference in the preva-
lence of C-PE in asylum seekers arriving in Rhineland-
Palatinate compared to that of the German community’. 
We used population prevalence estimates based on a 
study from Valenza et al. [17], who reported one C-PE in 
3,344 individuals (0.03%; 95% CI: 0.00–0.17) in a com-
munity-based sample in Germany. Based on this, we 
considered a prevalence of 0.20% or higher in asylum 
seekers to be of public health relevance. Using 80% 
power, an α-error of 5%, and a one-sided comparison 
against a fixed population value, we calculated to enrol 
1,512 individuals using the ‘sampsi’ command in Stata 
14 (StataCorp LP, College Station, Texas, United States 
of America). A maximum period of 12 months was pre-
determined in case the desired sample size would not 
be met.
Figure 1
Description of study sample from newly arrived asylum 
seekers, Germany, April 2016–March 2017
1,544 individuals tested
(955 males / 589 females)
3 isolates / 2 individuals 
with ESBL-phenotype in 
non-Enterobacteriaceae
2 isolates / 1 individual 
without ESBL genotype314 isolates / 294 individuals genotypic and 
phenotypic ESBL-PE
319 isolates /
 297 individuals with ESBL phenotype
No individuals with C-PE
ESBL: extended-spectrum β-lactamase; ESBL-PE: extended-
spectrum β-lactamase-producing Enterobacteriaceae; 
C-PE: carbapenemase producing Enterobacteriaceae.




Stool samples were sent to a diagnostic laboratory 
(Labor 28 GmbH, Berlin, Germany) for isolation of 
Enterobacteriaceae and ESBL phenotyping. All sam-
ples were spread on chromogenic screening agar 
(Brilliance ESBL agar, Oxoid, Wesel, Germany). Single 
colonies of different morphotypes were further cul-
tured and bacterial species were identified using the 
Vitek 2 system (bioMérieux, Nürtingen, Germany). 
Susceptibilities to amoxicillin, amoxicillin/clavulanic 
acid, mezlocillin, piperacillin, piperacillin/tazobac-
tam, tigecycline, cefuroxime, cefotaxime, cefepime, 
ceftazidime, cefpodoxime, ceftriaxone, imipenem, 
meropenem, ertapenem, gentamicin, tobramycin, cip-
rofloxacin, moxifloxacin, levofloxacin, trimethoprim 
and trimethoprim/sulfamethoxazole were determined 
and the results interpreted according to the European 
Committee on Antimicrobial Susceptibility Testing 
(EUCAST) breakpoints [20]. All isolates with ESBL 
phenotype (resistance to cefotaxime and/or ceftazi-
dime and/or ESBL phenotype according to the auto-
mated expert system implemented in Vitek 2 system) 
were sent to the Robert Koch Institute, Wernigerode, 
Germany, for molecular analyses.
Presence of various β-lactamase genes (bla  VIM-
like,  bla  NDM-like,  bla  OXA-48-like,  bla  NDM-like,  bla  CTX-M-1–2-
9group,  blaTEM-like,  bla  SHV-like,  bla  CMY-like,  bla  OXA-1-group,) 
was tested by PCR and sequencing using previ-
ously described primers [21-23]. Additionally, a PCR 
screening for plasmid-mediated genes contributing 
to resistance to fluoroquinolones (aac(6’)Ib-cr,  qnrA/
B/S-like) was performed as described [24,25]. For 
PCR screening of  qnrC  and  qnrD  genes, the following 
primers were used: qnrC  fwd 5’- atttccaaggggcaaactg-
3’and qnrC rev 5’-aactgctccaaaagctgctc-3’(amplification 
product 400bp),  qnrD  fwd 5’-ttgtgatttttcaggggttg-3’ 
and  qnrD  rev 5’- cctgctctccatccaacttc-3’ (amplification 
product 521bp). Possible presence of plasmid-mediated 
colistin resistance genes  mcr-1  and  mcr-2  was tested 
by PCR as described [26,27]. For  Escherichia coli  iso-
lates, the PCR-based identification of the four main 
phylogenetic groups was performed as described 
[28]. Furthermore, the proportion of  E. coli  multilo-
cus sequence type (ST) ST131 was determined by 
PCR-based assays identifying the clonal lineages  E. 
coli O25b:H4-ST131 and O16:H5-ST131 [29,30].
Data analysis and statistics
All records were stored in an EpiData database and 
imported into Stata 14. Countries were grouped by 
region according to United Nations (UN) standard M49 
[31]. Age was categorised in steps of 10 years, with indi-
viduals aged 40 years and over being combined in the 
‘40+’ group. Based on the binomial distribution, exact 
confidence intervals (CI) were calculated for preva-
lence estimates, using 95% CI as default and one-sided 
97.5% CI for the upper limit of zero frequencies.
To determine potential risk factors for ESBL-PE/C-PE 
colonisation, we analysed the influence of age, sex and 
geographic origin on colonisation using cross tabula-
tion as well as uni- and multivariable logistic regres-
sion modelling. We allowed for interaction between the 
explanatory variables and kept the interaction term, if 
a likelihood ratio test indicated improved model fit.
Ethical considerations
The study protocol was reviewed and approved by 
the ethics commission, board of physicians, Federal 
State of Rhineland-Palatinate, Germany (ref. number 
837.487.15).
Results
In total, 1,544 individuals were screened, of whom 
955 (62%) were male and 589 (38%) were female; the 
median age was 23 years for both men (inter quartile 
range: 17–32 years) and women (inter quartile range 
16–34 years). Asylum seekers from Syria were the most 
prominent group (n = 324), followed by Afghanistan 
(n = 282), Eritrea (n = 192), Iran (n = 170), Somalia 
(n = 161), and Pakistan (n = 115). Bacterial growth on 
ESBL screening agar was detectable for stool samples 
from 297 individuals. Three non-Enterobacteriaceae 
isolates (Pseudomonas aeruginosa, Pseudomonas 
putida,  and  Acinetobacter baumannii) with third 
Figure 2
Prevalence of ESBL-PE colonisation among asylum 
seekers, by country/region of origin, Germany, April 
2016–March 2017 (n = 1,544)
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ESBL-PE: extended-spectrum β-lactamase-producing 
Enterobacteriaceae.
Bars represent 95% confidence intervals. Sample size by category 
was Afghanistan/Pakistan/Iran (n = 166/567), Syria (n = 66/324), 
Eritrea/Somalia (n = 42/353), other (n = 20/300). The ‘Other’ 
category contains results from subjects from Albania (n = 0/48), 
Armenia (n = 1/18), Azerbaijan (n = 2/16), Bosnia-Herzegovina 
(n = 2/25), Kosovo* (n = 0/10), The Republic of North Macedonia 
(n = 3/23), Serbia (n = 0/11) and from 149 individuals (12 positive) 
from countries with less than 10 samples each. P value < 0.001 from 
χ2 test comparing proportion of ESBL-PE-positive individuals over 
strata of origin.
*This designation is without prejudice to positions on status, and 
is in line with UNSCR 1244/1999 and the ICJ Opinion on the Kosovo 
declaration of independence.
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generation cephalosporin resistance, but neither car-
bapenem resistance nor carbapenem non-susceptibil-
ity were found in stool samples of two individuals and 
were subsequently excluded from the study.
In total, 316 isolates of Enterobacteriaceae with ESBL 
phenotype (310  E. coli, three  Klebsiella pneumoniae, 
two Morganella morganii, and one Citrobacter freundii) 
were detected in stool samples from 295 individuals. 
Twenty-one of these individuals supplied stool sam-
ples, which contained two different isolates (20 con-
tained different  E. colimorphotypes, one contained  E. 
coli and M. morganii). In two of the 316 isolates (M. mor-
ganii, C. freundii), no ESBL genes could be detected. A 
subsequently performed disk test for ESBL/AmpC pro-
duction (D68C ESBL/AmpC ID MAST-group) confirmed 
both isolates as AmpC producers, probably due to spe-
cies-specific chromosomal encoded enzymes. Thus, 
both isolates (one individual) were excluded, leaving 
314 isolates from 294 individuals for the analysis of 
phenotypic and genotypic resistance (Figure 1).
C-PE and ESBL-PE colonisation
Our final sample included 1,544 individuals, of whom 
294 tested positive for ESBL-PE (19.0%, 95% CI: 17.0–
21.0), with a total of 314 isolates containing ESBL 
genes (310  E. coli, three  K. pneumoniae, one  M. mor-
ganii) (Figure 1). Stratifying the results showed that 
prevalence of ESBL-PE colonisation varied by county/
region of origin (chi-squared p < 0.001). Highest preva-
lences were observed in individuals from Afghanistan/
Pakistan/Iran 29.3% (n = 166/567; 95% CI: 25.6–33.2), 
followed by Syria 20.4% (66/324; 95% CI: 16.1–25.2), 
and Eritrea/Somalia 11.9% (42/353; 95% CI: 8.7–15.7). 
Samples combined in the “Other” category included 
300 individuals (ESBL-PE positive: n = 20 (6.7%); 95% 
CI: 4.1–10.1), originating from the following countries: 
Albania (n = 0/48), Bosnia-Herzegovina (n = 2/25), 
The Republic of North Macedonia (n = 3/23), Armenia 
(n = 1/18), Azerbaijan (n = 2/16), Serbia (n = 0/11), 
Kosovo* (n = 0/10), as well as 149 individuals (12 posi-
tive) from countries with less than 10 samples each 
(Figure 2).
 
As shown in Figure 3, prevalence of ESBL colonisation 
varied by age group and sex, with a range over catego-
ries of age and sex from 13% to 27%. Highest preva-
lences were observed in boys under 10 years (25.6%; 
95% CI: 18.0–34.5), and in women aged 20–29 years 
(24.4%; 95% CI: 17.3–32.7) and 30–39 years (23.2%; 
95% CI: 15.8–32.1). A likelihood ratio test comparing 
multivariable regression models of the association 
of sex and age with ESBL-prevalence showed better 
model fit when allowing for interaction between age 
and sex (p value = 0.03) (Figure 3).
No C-PE were detected in any of the samples, result-
ing in a prevalence estimate of 0.0% (upper 97.5% 
confidence limit 0.2%) for the overall population of 
asylum seekers. There was no evidence to reject the 
null hypothesis of C-PE in asylum seekers being equal 
to that previously reported in the German population 
(fixed population prevalence 0.20%, p value = 0.75). 
Based on sample size and according precision in esti-
mating the proportion of C-PE in respective strata, 
the 0% C-PE prevalence estimates had upper one-
sided 97.5% confidence limits of 1.1% for Syria, 0.6% 
for Afghanistan/Pakistan/Iran, and 1.0% for Eritrea/
Somalia, respectively.
Antibiotic resistance
The 314 isolates with ESBL genes (310 E. coli, three K. 
pneumoniae, one M. morganii) were resistant to penicil-
lines and 3rd  generation cephalosporins. Furthermore, 
they showed additional resistance to ciprofloxacin, 
gentamicin, and trimethoprim-sulfamethoxazole in 
33% (n = 103), 16% (n = 51), and 63% (n = 199), respec-
tively. Intermediate susceptibility to tigecycline was 
detected in two K. pneumoniae isolates.
Genetic determinants of antibiotic resistance
Table 1  summarises the results of the molecular 
characterisation of ESBL-PE, and  Table 2  shows 
additional β-lactamase and plasmid-mediated 
quinolone resistance (PMQR) genes, stratified by 
geographic region. The two most prevalent ESBL genes 
were  bla  CTX-M-15  (n=249; 79%) and  bla  CTX-M-27  (n=30; 
10%). Four isolates (1.3%) with ESBL gene  bla  CTX-
M-15  ESBL carried additional  ampC  genes (bla  CMY-
4,  bla  CMY-42,  bla  CMY-58, and  bla  CMY-59). β-lactamase 
Figure 3
Prevalence of ESBL-PE colonisation among asylum 
seekers, by age category and sex, Germany, April 2016–























ESBL-PE: extended-spectrum β-lactamase-producing 
Enterobacteriaceae.
Bars represent 95% confidence intervals.
Likelihood ratio test for interaction between age and sex gives a p 
value of 0.03.
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genes bla TEM-like and bla OXA-1 were found in 125 (39.8%) 
and 43 (13.7%) of the ESBL producing isolates, 
respectively. The three K. pneumoniae  isolates carried 
different  bla  SHV  genes (bla  SHV-1,  bla  SHV-11,  bla  SHV-75) 
in combination with ESBL gene  bla  CTX-M-15. A sub-
stantial amount of the ESBL-PE isolates were posi-
tive for the  qnrS1 gene  (81/314, 25.8%) contributing 
to fluoroquinolone resistance; other variants 
(qnrB1, 3/314, 1.0%; qnrB19, 3/314, 1.0%; qnrA1, 1/314, 
0.3%) and methytransferase gene aac(6’)Ib-cr (40/314, 
12.7%) were found in small numbers. Plasmid-mediated 
colistin resistance genes mcr-1 or mcr-2 were not found 
in any of the ESBL-PE.
Characterisation of E. coli and its epidemic 
lineages
PCR screening revealed that E. coli-ST131 accounted for 
24.4% of all ESBL-E. coli. Colonisation with epidemic 
ESBL-producing  E. coli-ST131 clonal sublineages O16 
and O25b varied by region of origin with O16 being 
predominantly from Syria and O25b from Eritrea and 
Somalia (Table 3). Phenotypic non-susceptibility to 
ciprofloxacin was detected in nearly all ST131-O25b 
(41/49) and many non-ST131  E. coli  (67/234), but 
was rare in ST131-O16 (3/26).  Supplementary Table 
S1 displays β-lactamase- and PMQR genes in E. coli and 
its epidemic lineage ST131.
Discussion
We conducted a large cross-sectional study on the 
prevalence of C-PE in newly arrived asylum seekers 
in Rhineland-Palatinate. Despite ample sample size 
and statistical power, our study did not find evidence 
supporting a higher C-PE prevalence in asylum seek-
ers compared with that reported in the German com-
munity. Hence, it is unlikely that being a newly arrived 
asylum seeker from a country/region with increased 
prevalence of ESBL-PE colonisation alone, i.e. in the 
absence of morbidity that increases the likelihood of 
carbapenem use and/or hospitalisation before arrival 
in Europe, is a risk factor for C-PE colonisation and 
thus, should not be a reason for screening on admis-
sion to regular hospital wards.
A recent study reported C-PE colonisation in six of 
290 asylum seekers (2.1%) who were screened upon 
hospital admission in Germany [16], which is contrary 
to what we found. The difference, however, could be 
explained by the different populations studied, with 
results from the hospital-based study likely influenced 
by patients with pre-morbidities and associated risk 
of C-PE colonisation, and therefore not representative 
for the overall population. Such differences re-inforce 
the need for both, community-based prevalence stud-
ies and an individual risk assessment upon hospital 
admission.
We found that the prevalence of ESBL-PE (i.e. non-
C-PE) colonisation in newly arrived asylum seekers 
exceeds that of the population residing in Germany, 
which is assumed to be 2–6% in the community [17,32] 
and slightly higher (7–10%) in hospitalised patients 
[33,34]. With more than 29% of asylum seekers from 
Afghanistan, Pakistan and Iran, 20% from Syria and 
12% from Eritrea and Somalia testing positive for 
ESBL-PE colonisation, the prevalences detected in our 
Table 1
Extended-spectrum β-lactamases in Enterobacteriaceae from 1,544 newly arrived asylum seekers, by country/region of 













n % n % n % n % n %
CTX-M-15 249 79 158 86 51 75 30 71 10 48
CTX-M-27 30 10 15 8 5 7 4 10 6 29
CTX-M-1 7 2 1 1 4 6 2 5 0 0
CTX-M-3 8 3 2 1 4 6 1 2 1 5
CTX-M-55 6 2 4 2 0 0 2 5 0 0
SHV-12 4 1 1 1 0 0 1 2 2 10
CTX-M-14 4 1 0 0 2 3 1 2 1 5
CTX-M-24 2 1 1 1 1 1 0 0 0 0
CTX-M-9 1 0 0 0 1 1 0 0 0 0
CTX-M-17 1 0 0 0 0 0 0 0 1 5
ESBL: Extended-spectrum β-lactamase.
a Grouped according to United Nations Regions M49 standard [31].
b Includes isolates from countries with less than five positive stool samples.
Data are number (column %) of detected ESBL genes (PCR and sequencing) in Enterobacteriaceae from asylum seekers (total N), by country 
of origin, unless indicated otherwise. P value for chi-squared test of the null hypothesis: ‘Presence of any of these extended spectrum 
β-lactamase genes in ESBL isolates is equally distributed over countries/regions of origin’ is < 0.001.
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study are in line with estimates for south-east Asia 
(22%, 95% CI 7-44), eastern Mediterranean (15%, 95% 
CI 4-31), and Africa (22%, 95% CI 5-47) published by 
Karanika et al. [35] who combined the evidence of 
research on ESBL prevalence in 28,909 community 
dwellers in their large meta-analysis.
On the other hand, our estimates are considerably 
lower than those reported in a systematic review of 
ESBL colonisation prevalence in long-distance travel-
lers returning to Europe; prevalence’s were reported 
to be over 70% in travellers returning from south- and 
south-east Asia [4]. Travellers’ diarrhoea and antibiotic 
use, both very common in travellers, were identified as 
risk factors for ESBL-PE colonisation [36]. The majority 
of travellers returning from long-distance travel clear 
ESBL-PE colonisation within the first month, with less 
than 10% still being colonised after 3 months [37]. 
Hence, apart from geographic variation in the colonisa-
tion risk, a predominance of ground- vs air-travel could 
explain the lower ESBL-PE colonisation prevalence 
observed in our sample of asylum seekers compared 
with long-distance travellers.
From a public health point of view, this puts our findings 
into perspective. First, considering the large number of 
air travellers returning to Europe from high prevalence 
countries each year, ESBL-PE faecal colonisation in 
asylum seekers is probably a minor contributor to the 
overall burden of ESBL-PE import. Second, as observed 
in travellers [37], ESBL-PE colonisation in asylum seek-
ers is likely temporary. Thus the prevalence of coloni-
sation should decrease to that of the population living 
in the host country after a few months. To confirm the 
latter hypothesis, research on the duration and risk 
factors of faecal ESBL-PE carriage in newly arrived asy-
lums seekers is needed.
A recent review discussing enhanced contact pre-
cautions for all in-patients colonised with ESBL-
producing  E. coliconcluded that the evidence base for 
their implementation is ‘rather weak’ [38] and currently 
these are not recommended by European guidelines 
[39]. In Germany, screening for ESBL-PE other than CPE 
is currently not recommended upon hospital admission 
and enhanced infection control measures for patients 
colonised with these bacteria are only recommended 
on high-risk wards (i.e. neonatology, haematology 
and intensive care units) [40]. Hence, our findings on 
ESBL-PE (i.e. non-C-PE) colonisation in newly arrived 
asylum seekers being predominantly caused by E. coli, 
do not warrant additional infection control measures. 
However, they may help to guide the choice of diagnos-
tic tests, calculated antibiotic therapy, as well as the 
planning of invasive procedures in newly arrived asy-
lum seekers.
Table 2
β-lactamase- and plasmid-mediated quinolone resistance genes in ESBL-producing Enterobacteriaceae from 1,544 newly 














n % n % % n % n %
blaTEM
e 125 40 69 38 n = 68 50 14 33 8 38 NA
blaOXA-1
e 43 14 22 12 8 12 10 24 3 14 NA
blaCMY-4/42/58/59(AmpC) 4 1 4 2 0 0 0 0 0 0 NA
blaSHV-1/11/75 3 1 2 1 1 1 0 0 0 0 NA
Total 
additional bla genes 175 56 97 53 43 63 24 57 11 52 0.53
aac(6‘)Ib-cr 40 13 19 10 8 12 10 24 3 14 NA
qnrA1 1 0 0 0 1 1 0 0 0 0 NA
qnrB1 3 1 2 1 1 1 0 0 0 0 NA
qnrB19 3 1 1 1 2 3 0 0 0 0 NA
qnrS1 81 26 61 33 10 15 7 17 3 14 NA
Total quinolone 
resistance genes 128 41 83 45 22 32 17 40 6 29 0.18
ESBL: extended-spectrum β-lactamase; NA: not applicable.
a Plasmid-mediated colistin resistance genes mcr-1 or mcr-2 were not found in any of the ESBL-producing Enterobacteriaceae.
b Grouped according to United Nations Regions M49 standard [31].
c Includes isolates from countries with less than five positive stool samples.
d P value for chi-squared test testing the null hypothesis: ‘Presence of any β-lactamase/any plasmid-encoded quinolone resistance genes 
among all ESBL isolates is equally distributed over countries of origin’.
eblaTEM and blaOXA-1-group genes were not completely sequenced.
Data are number (column %) of detected β-lactamase/plasmid-mediated quinolone resistance (PMQR) genes among ESBL-producing 
Enterobacteriaceae (total N), by country of origin, unless indicated otherwise. All blaTEM, blaOXA-1-group, blaSHV, blaCMY and PMQR genes occurred 
in combination with ESBL genes (blaCTX-M).
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We observed that sex modified the effect of age on 
ESBL-PE colonisation prevalence. The odds of ESBL-PE 
colonisation were highest in young males under 10 
years and between the age of 30 and 39 years and in 
females between 20 and 39 years. The latter finding 
has also been described in other studies [41] and could 
potentially be explained by a higher incidence of uri-
nary tract infections and associated antibiotic therapy 
in women of reproductive age.
Molecular analyses of ESBL-PE isolated in this study 
showed a dominant proportion of CTX-M-15 followed 
by CTX-M-27. CTX-M-15 is the most prevalent ESBL 
determinant worldwide and was also reported in up to 
50% of ESBL-PE positive stool samples from Germany 
[17,42,43]. We found 24% of epidemic lineage  E. coli-
ST131 among ESBL-PE of asylum seekers, which is 
comparable to proportions in isolates from commu-
nity dwellers, ambulatory and hospitalised patients in 
Germany [43]. From a public health point of view, this 
is relevant, since E. coli-ST131 and particularly the sub-
lineage ST131-O25b is more virulent [44] and known 
to cause large outbreaks in both, the community and 
healthcare setting [45,46].We further observed that E. 
coli-ST131 mainly produced CTX-M-15 and CTX-M-27 
(Supplementary Table S1). Of note, CTX-M-27 accounted 
for a third of all ESBL genes harboured by ST131 and 
half of those in ST131-O25b. The finding of CTX-M-27 
in ESBL-PE from asylum seekers from all geographic 
regions supports the notion of its successful world-
wide expansion, as proposed by Matsumura et al. [47]. 
Our findings support other studies that propose human 
travel as a main driver for the temporal and geographi-
cal shift in CTX-M-producing Enterobacteriaceae [48] 
and the  E. coli-ST131 epidemic lineages [49]; a public 
health response that goes beyond targeting asylum 
seekers is now awaited.
This study has some limitations. First, precise informa-
tion on travel routes and time would have been desir-
able, but could not be collected as stool samples from 
routine screening were used. However, this does not 
impact the main finding of a low prevalence of C-PE col-
onisation among asylum seekers in Germany. Second, 
we have no information regarding recent contact to the 
healthcare setting (e.g. hospital) or use of antibiotics. 
With regards to C-PE prevalence, our main outcome 
of interest, inclusion of ‘pre-morbid asylum seekers’ 
with an increased risk of antibiotic intake and/or hos-
pitalisation compared to ‘community dwellers’ would 
lead to an overestimation. Therefore, we assume that 
this information bias has not affected our 0% preva-
lence finding. Finally, like other studies on the import 
of ESBL-PE and C-PE to Europe through international 
travel [3], we were not set up to detect OXA-48-like 
producers without ESBL phenotype through the use of 
ESBL screening agar.
In summary, our study detected no faecal colonisa-
tion with C-PE in 1,544 newly arrived asylum seekers. 
These data support the notion that being an asylum 
seeker from a country/region with increased ESBL-PE 
colonisation prevalence alone is not an indicator for 
C-PE colonisation upon arrival in Germany and thus not 
a reason for pre-emptive screening or isolation upon 
hospital admission.
Note
*This designation is without prejudice to positions on sta-
tus, and is in line with UNSCR 1244/1999 and the ICJ Opinion 
on the Kosovo declaration of independence.
Table 3
Proportion of Escherichia coli-ST131 in ESBL-producing E. coli, detected in 1,544 newly arrived asylum seekers arriving in 














n % n % n % n % n %
Total E. coli ST131 75 24 34 19 23 34 14 34 4 19 0.029d
ST131-O16 26 8 11 6 13 19 2 5 0 0
0.022e
ST131-O25b 49 16 23 13 10 15 12 29 4 19
ESBL: extended-spectrum β-lactamase; H0: null hypothesis.
a The sequence type of one out of n = 310 E. coli isolated from asylums seekers could not be determined by PCR (ambiguous results).
b Grouped according to United Nations Regions M49 standard [31].
c Includes isolates from countries with less than five positive stool samples.
d P value from chi-squared test testing H0: ‘The proportion of E. coli ST131 among all ESBL-producing E. coli (100%) is equally distributed over 
countries of origin’.
e P value from chi-squared test testing H0: ‘Among ESBL-producing E. coli  ST131 (100%), the proportions of E. coli  ST131 serotypes O16 and 
O25b are equally distributed over countries of origin’.
Data are number (column %) of clonal lineages ST131-O16 and ST131-O25b among ESBL-producing E. coli  (total N), by country of origin.
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